HUMA at a glance
Humacyte, Inc. (HUMA, SEC CIK 1818382) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Humacyte, Inc. (HUMA) shares worth $10.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Jones Keith Anthony on September 14, 2026 of 10,000 shares at $0.56 per share.
- In the last 90 days, HUMA insiders reported 1 open-market purchase ($6K) and 0 open-market sales ($0) on Form 4, a net purchase of $6K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.0M
- 10-K XBRL
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$6K
- 13F holders
- 24 funds
- $10.9M · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1.0M, up from $0.8M YoY, driven by Symvess product sales
- Operating loss $23.5M vs $24.4M YoY, operating margin -2,288.3% vs -3,048.8%
- Symvess product revenue $1.0M vs $0.7M, the only reported product line
- Cash, equivalents and restricted cash $64.9M, up from $19.8M; operating cash use $62.1M vs $78.9M
- Going-concern risk, insufficient liquidity beyond one year without higher Symvess sales or additional capital
Risk Factors
- Cost-saving execution risk: May 2026 workforce reduction of approximately 45 employees
- Nasdaq compliance risk: $1.00 bid-price requirement, with compliance deadline January 27, 2027
- Delisting financing risk: Nasdaq removal could impair liquidity and capital-raising ability
- Workforce disruption risk: severance costs could negatively impact cash flows
- Talent retention risk: unplanned attrition could reduce productivity and organizational knowledge
AI summary of the HUMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q3 2026 results for quarter ended September 30, 2026
- Humacyte press release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.1: Item EX-99.1
- Symvess Q3 sales $1.0M, up 151% sequentially and 45% year over year, with ordering hospitals rising 44% to 49
- October sales reached $0.8M, while management targets at least doubling Q3 sales in Q4, supporting commercial traction but raising execution expectations
Item EX-99.1: Item EX-99.1
- Board additions target commercialization and global operations as Humacyte expands Symvess launch and prepares dialysis-access ATEV launch
- Scott Coward adds public-company governance, M&A integration, legal, and compliance expertise through Audit Committee appointment
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expansion adds Scott Coward as Class I director through 2028 and Paul Kuznik as Class II director through 2029
- Coward joins Audit Committee, adding public-company governance, legal, M&A and integration expertise
Item 7.01: Regulation FD Disclosure
- Board appointments of Mr. Coward and Mr. Kuznik announced on September 28, 2026
- New director additions may influence governance, oversight and strategic direction
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 sales rose to $0.4M from $0.1M, but $1.2M cost of goods sold reflects a $0.7M inventory reserve and unused capacity costs
- V012 Phase 3 interim results showed 91 additional catheter-free days and infection rates of 6 versus 23 per 100 patient years
AI summaries of HUMA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HUMA
Don't miss the next HUMA filing
- Alerts as it files. A push when HUMA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HUMA, by share count.
- Ask anything. An AI agent that reads every HUMA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| COWARD D SCOTT | A | Oct 6, 2026 | 125,000 | - |
| Kuznik Paul Brian | A | Oct 6, 2026 | 125,000 | - |
| Jones Keith Anthony | Buy | Sep 14, 2026 | 10,000 | $0.56 |
| Jones Keith Anthony | Buy | Aug 20, 2026 | 10,000 | $0.69 |
| Jones Keith Anthony | Buy | Aug 17, 2026 | 30,000 | $0.59 |
| Windham-Bannister Susan Richards | A | Jun 11, 2026 | 80,000 | - |
| Constantino Michael T. | A | Jun 11, 2026 | 80,000 | - |
| Brown Emery N. | A | Jun 11, 2026 | 80,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $2.0M |
| Operating Income | -$100.0M | -$114.4M | -$108.1M |
| Net Income | -$110.8M | -$148.7M | -$40.8M |
| Op. Margin | - | - | -5306.0% |
| Net Margin | - | - | -2003.6% |
| Balance Sheet | |||
| Total Assets | - | $137.9M | $116.4M |
| Equity | $13.5M | -$52.7M | $3.1M |
| ROE | -817.8% | 282.3% | -1313.4% |
| Per Share | |||
| EPS | - | $-1.26 | $-0.26 |
| Cash Flow | |||
| Operating CF | -$73.3M | -$98.1M | -$105.0M |
| CapEx | - | $1.6M | $884K |
Source: XBRL data in Humacyte, Inc. (HUMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HUMA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $10.9M |
| Q2 2026 | 25 | $19.3M |
| Q1 2026 | 27 | $18.0M |
| Q4 2025 | 25 | $32.7M |
| Q3 2025 | 27 | $49.9M |
| Q2 2025 | 25 | $67.1M |
| Q1 2025 | 24 | $34.6M |
| Q4 2024 | 18 | $73.1M |
- Vanguard Capital Management LLC+856.4K (+8%)
- Citadel Advisors LLC+289.8K (+20%)
- Vanguard Portfolio Management LLC+199.0K (+35%)
- Invesco Ltd+193.1K (+76%)
- Northern Trust+130.1K (+29%)
- AQR Capital Management−2.48M (-96%)
- Bank of America Corp−490.1K (-85%)
- Goldman Sachs Group−343.6K (-59%)
- BlackRock−274.3K (-6%)
- Morgan Stanley−84.6K (-25%)
- Renaissance Technologies LLC+110.3K
- Truist Financial+10.0K
- Millennium Management−1.91M
- Equitable Holdings Inc−20.0K
- FMR LLC (Fidelity)−19.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HUMA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| SC 13G | Jun 22, 2026 | - | - | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
HUMA SEC filings: frequently asked questions
Are HUMA insiders buying or selling?
In the last 90 days, Humacyte, Inc. (HUMA) officers, directors and 10% owners reported 1 open-market purchase worth $5,620 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HUMA stock?
As of September 30, 2026, the largest Humacyte, Inc. (HUMA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.7 million), BlackRock ($2.4 million), Citadel Advisors LLC ($897,000), State Street Corp ($466,000), Vanguard Portfolio Management LLC ($398,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HUMA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26. The figures come from the XBRL data in the 10-K.
What did HUMA report in its latest 8-K?
Humacyte, Inc. (HUMA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q3 2026 results for quarter ended September 30, 2026.
What are the latest HUMA SEC filings?
Humacyte, Inc. (HUMA) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 7, 2026.
What is HUMA's SEC CIK number?
Humacyte, Inc. (HUMA)'s SEC Central Index Key (CIK) is 1818382. EDGAR lists every HUMA filing under that number.
Ask anything about HUMA
The research agent reads HUMA's filings, financials, insider trades and 13F holders, then answers with sources.